Navigation Links
Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs

Early stage compounds and new filings targeted in five therapeutic areas

Expanding indications for strong core products builds "pipeline in a product"

Leveraging global capabilities and reach drives growth efforts in emerging markets

Biomarkers and diagnostics combine with therapies to advance personalized medicine

Company's vision focuses on improving human health and reducing global burden of disease

NEW BRUNSWICK, N.J., June 4 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) will be reviewing the growth strategies and pipeline for its Pharmaceutical business at a meeting with the investment community today. Senior leaders from the company's pharmaceutical segment will outline how continued expansion of its core products, progress in its pipeline, and an end-to-end approach to its research and development (R&D) will fuel its long-term growth and address unmet medical needs.

The company will highlight its plans for addressing these needs in five therapeutic areas:

  • Neuroscience -- Johnson & Johnson is a leader in neuroscience, which not only includes central nervous system (CNS) disorders, but also treatment of pain -- both acute and chronic. The company will continue to focus on its traditional areas of strength and high unmet need -- schizophrenia, epilepsy, bipolar disorder and pain -- while taking a different approach to neuroscience drug development, including greater emphasis in the future on cognition and dementia.

  • Cardiovascular disease and Metabolism -- In this area, the company is focused on three major conditions -- cardiovascular disease, diabetes, and obesity -- where incidence rates are soaring, placing a tremendous burden on patients as well as the global healthcare system. This expanding portfolio is being built to address the growing need for new treatment options in this category.

  • Immunology -- In this area, the company's focus is on inflammation. An estimated 50 million Americans suffer from diseases of the immune system, and there are approximately 10 million people living with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.

  • Infectious Diseases -- The company is extending its leadership in HIV and expanding into another virology market, hepatitis C. Its portfolio in this area also includes broad-spectrum antibiotic drugs for the treatment of a wide range of infections.

  • Oncology -- The company's strategy in oncology is focused on targeting both the tumor and tumor microenvironment, with an aim to prevent, treat, or cure cancer through a targeted approach to developing therapies.

Brief summaries of the therapeutic areas, products and compounds being discussed in today's presentations are available in this backgrounder: Pharmaceutical Segment Review Highlights.

Pharmaceutical Growth Strategies

Johnson & Johnson's pharmaceutical businesses generated $24.6 billion in sales last year, 39 percent of the company's total revenue, and ranks as the world's seventh largest pharmaceutical company and fourth largest biotech company. Its portfolio includes nine products that delivered more than $1 billion in sales in 2008. Its recent pace of regulatory filings, approvals and line extensions place it among the industry leaders and its robust pipeline positions it well for continued success.

"We are very optimistic about our future in pharmaceuticals," says Worldwide Chairman of Pharmaceuticals Sheri McCoy. "We are well-positioned with an industry-leading pipeline, the global reach and financial resources of Johnson & Johnson, a long, rich history in pharmaceuticals, and a broad portfolio that is grounded in science and addresses serious unmet needs."

With the pharmaceutical market at an estimated $750 billion globally, McCoy will outline five strategies for growth for the company's pharmaceutical businesses:

  • Grow the core global product portfolio -- The company is focused on growing share in its core products (e.g., REMICADE(R), RISPERDAL(R) CONSTA(R) and CONCERTA(R)) through greater market penetration, new commercial models and an expanded geographic presence. Additionally, it will focus on lifecycle management of its products as exemplified by REMICADE, which is itself a "pipeline in a product" with 15 indications and ongoing clinical trials.

  • Successfully execute product launches -- The company has several key products launching (e.g., SIMPONI(TM) and NUCYNTA(TM)) and has seven compounds filed and awaiting approvals.

  • Continue building a robust pipeline -- The company is focused on the best science and actively pursues various sources of innovation (internal development, licensing, acquisitions and academic partnerships), which enable it to advance its work on specific diseases in five therapeutic areas. Its capabilities in biomarkers and diagnostics distinguish the company as a leader in the future of personalized medicine.

  • Accelerate growth in emerging markets -- With 95 percent of the world's patients and much of the growth in health care occurring outside the U.S., the company continues to use its global presence, decentralized operating model and productive relationships to serve local unmet medical needs around the world.

  • Participate in dialogues shaping health care policy -- Through its participation in global health care policy dialogues, the company is part of the effort to reduce the global burden of disease by driving greater efficiencies and increased access to affordable health care.

Fueling Growth Through Innovation

Paul Stoffels, M.D., global head of Research and Development for Pharmaceuticals, will report today on the business' recent track record of pipeline productivity and its long-term strategy for addressing some of the most important unmet medical needs in the world today.

"Our pipeline productivity is on track. In fact, 2008 was a year of significant submissions and approvals for us," says Stoffels. "We had six new compounds approved in major markets, and we have seven compounds with filings pending in the U.S. and Europe. We also had outstanding late-stage development progress, with five compounds advancing to late development. And, finally, we expanded our portfolio through licensing, collaborations, and creating new partnerships in emerging regions such as India and China."

Johnson & Johnson invested just over $5 billion in pharmaceutical R&D programs last year. "Innovation and sustained R&D productivity are key to our long-term future," says Stoffels. "The future drivers for success in pharmaceuticals will depend on matching the medical need with the best science and operational excellence. It will require that we have a therapeutic area focus, an open innovation approach, an outcomes-based drug development strategy, broad-based expertise and global reach, and truly outstanding people."

The company is continuing to advance its pipeline of new compounds, while also exploring line extensions for existing drugs, which have the potential to become what the company calls a "pipeline in a product." Among some of the early stage compounds being discussed today are the company's first compound for treating type 2 diabetes, the SGLT2 inhibitor, and CNTO-888, which has the potential for indications in both immunology and oncology. Stoffels and other executives will discuss the company's expectations for new filings and early-stage compounds across each of the five therapeutic areas throughout the day.

"Our pipeline is robust and consists of compounds that are differentiated and meet unmet needs in global and large regional markets. And our commercial teams around the world are working to deliver enhanced clinical and economic value," says McCoy. "All of this together gives me great confidence in our ability to make a real difference in patients' lives."

Full copies of the presentations as well as a replay and podcast will be available approximately two hours after the live webcast concludes at

About Johnson & Johnson

Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents obtained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at, or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.

This press release contains statements about new molecular entities ("NMEs") and other medicines or line extensions in various stages of development. These statements are based on the Company's current knowledge of the status of development of these NMEs, medicines and line extensions and are subject to the challenges and difficulties inherent in product development. The Company assumes no obligation to update any statements regarding these NME, medicines or line extensions as a result of new information or future events or developments. In biopharmaceuticals, there are higher possibilities of encountering infringement claims by competitors with respect to patents or other intellectual property rights. The Company assumes no obligation to update any statements as a result of new information or future events or developments.)

SOURCE Johnson & Johnson
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
2. Boston Scientific Announces Two Directors Leave Board as Burns Named CEO of Xerox and Johnson Confirmed as Under Secretary of Energy
3. Champions Shawn Johnson & Phil Jackson Wear Energy Muse Jewelry
4. Johnson & Johnson to Participate in Deutsche Bank 34th Annual Health Care Conference
5. Johnson & Johnson to Host Analyst Conference Call To Review Six-Month Trial Results From NEVO RES I
6. EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results
7. Johnson & Johnson to Participate in Bank of America and Merrill Lynch 2009 Health Care Conference
8. Weill Cornell and Cornells Johnson School present first annual business and medicine symposium
9. Johnson & Johnson to Webcast Annual Meeting of Shareholders
10. Johnson & Johnson Reports 2009 First-Quarter Results:
11. Trust for Americas Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America
Post Your Comments:
(Date:11/25/2015)... ... 25, 2015 , ... Lakeview Health, a Jacksonville-based drug and ... sobriety and show through pictures what a positive difference it makes. The social ... the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories ...
(Date:11/25/2015)... , ... November 25, 2015 , ... The McHenry County ... recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. ... Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android ... The new app features a more intuitive SleepScore™ that rates sleep quality on a ... The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk Driving (MADD) ... below 10,000 for the first time since 2011. In 2014, there were 9,967 fatalities ... released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in ...
(Date:11/25/2015)... ... 2015 , ... Privately owned Contract Development and Manufacturing Organization ... current state of the art research, development and manufacturing facility outside of Fort ... capacity as well as to support its clients’ growing research and development and ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... 25, 2015 Kitov Pharma ... KTOV), a biopharmaceutical company focused on the development of ... conditions, today announced the closing of its previously announced ... ADSs ), each representing 20 ordinary shares of the ... The ADSs and warrants were issued in a fixed ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Today AVACEN Medical announced the issue of ... Thermal Energy Including Blood Viscosity Adjustment ". This patent shields the company,s AVACEN 100 dry heat ... Treatment Method. Photo - ... ... ...
Breaking Medicine Technology: